Vertex Pharmaceuticals Incorporated (VRTX) fair value analysis

S&P 500 · Updated 2026-09-07

Vertex Pharmaceuticals Incorporated is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases including cystic fibrosis, pain, and viral infections. The company operates globally with research and development facilities and commercial operations across multiple regions including North America, Europe, and other international markets.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, VRTX is trading at within about 10% of estimated fair value.

VRTX currently ranks #82 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $546.12
Sector: Healthcare
12-month range: $423.92–$547.65

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for VRTX

Our model validated 13 trailing price-to-earnings windows for VRTX, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $423.92–$547.65.
The 14-day relative strength index sits at a neutral 64.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for VRTX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent VRTX news

TickrTrends' derived news-sentiment signal for VRTX is currently leaning positive, computed from recent coverage.

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (zacks.com, 2026-09-08)
TickrTrends take: Vertex Pharmaceuticals operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. The elevated investor search activity reflects market interest in the company, though a fairly valued status suggests the current price already incorporates publicly available information and near-term expectations. Investors monitoring VRTX should consider whether upcoming clinical trial results, regulatory developments, or pipeline expansions might shift the valuation away from fair value territory.
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? (insidermonkey.com, 2026-08-14)
TickrTrends take: Vertex Pharmaceuticals operates in the Healthcare sector where the company is currently assessed as fairly valued by TickrTrends. A valuation-focused reader should monitor how the AbCellera partnership develops, as successful applications of the TCE platform could either validate the current valuation or create upside potential depending on the commercial outcomes of collaborative programs. The therapeutic value and market adoption of any resulting assets from this deal will be key to determining whether Vertex's current valuation appropriately reflects the opportunity.

What people are saying

Follow the VRTX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for VRTX showed a change in momentum classification this week, moving from a B rating to no momentum rating. The stock remains in the Fairly valued category according to current valuation assessment.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is VRTX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), VRTX is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is VRTX's TickrTrends verdict?

VRTX's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does VRTX compare to other Healthcare stocks?

VRTX ranks #82 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is VRTX overbought or oversold?

VRTX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

VRTX vs ABBV · VRTX vs ACHC · VRTX vs BIIB · VRTX vs BVS · VRTX vs HCSG